Compare Roopa Industries with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
INR 38 Cr (Micro Cap)
9.00
37
0.00%
1.68
23.98%
2.15
Total Returns (Price + Dividend) 
Roopa Industries for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Roopa Industries Downgraded to Sell Amid Technical Weakness and Fundamental Concerns
Roopa Industries Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 31 August 2026. This revision reflects a deterioration in technical indicators alongside mixed financial trends and valuation metrics, prompting a reassessment of the stock’s outlook despite some positive quarterly results.
Read full news article
Roopa Industries Ltd is Rated Sell
Roopa Industries Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 5 August 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 20 August 2026, providing investors with the most recent and relevant data to assess the stock’s outlook.
Read full news article
Roopa Industries Downgraded to Sell Amid Mixed Financials and Bearish Technicals
Roopa Industries Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 5 August 2026. This change reflects a deterioration in technical indicators despite the company’s very positive quarterly financial performance. Investors are advised to weigh the mixed signals from quality, valuation, financial trends, and technicals before making decisions.
Read full news article Announcements 
Announcement under Regulation 30 (LODR)-Newspaper Publication
18-Aug-2026 | Source : BSESubmission of Newspaper Clippings w.r.t publication of Unaudited Financial Results for the 1st Quarter Ended 30th June 2026
Submission Of Unaudited Financial Results
14-Aug-2026 | Source : BSESubmission of Unaudited Financial Results for the quarter ended 30/06/2026
Board Meeting Outcome for Submission Of Unaudited Financial Results And Intimation Of Outcome Of The Board Meeting Held On 14Th August 2026
14-Aug-2026 | Source : BSESubmission of Unaudited financial results and intimation of Outcome of the Board Meeting held on 14th August 2026
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Jun 2026
Shareholding Compare (%holding) 
Non Institution
None
Held by 0 Schemes
Held by 1 FIIs (0.25%)
Star Niochem Pvt Limited (18.91%)
Sangeetha S (9.51%)
41.0%
Quarterly Results Snapshot (Standalone) - Jun'26 - QoQ
QoQ Growth in quarter ended Jun 2026 is 10.55% vs -10.14% in Mar 2026
QoQ Growth in quarter ended Jun 2026 is 123.08% vs -285.71% in Mar 2026
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 6.15% vs 106.60% in Sep 2024
Growth in half year ended Sep 2025 is -12.79% vs 7.50% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 7.17% vs 87.94% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -6.17% vs 51.40% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is 5.64% vs 71.36% in Mar 2025
YoY Growth in year ended Mar 2026 is -96.06% vs 33.55% in Mar 2025






